916 related articles for article (PubMed ID: 21835642)
1. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery.
Singh SP; Chauhan S; Choudhary M; Vasdev S; Talwar S
Asian Cardiovasc Thorac Ann; 2012 Feb; 20(1):19-23. PubMed ID: 22371937
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII following pediatric cardiac surgery.
Kylasam S; Mos K; Fijtin S; Webster B; Chard R; Egan J
J Intensive Care Med; 2009; 24(2):116-21. PubMed ID: 19188273
[TBL] [Abstract][Full Text] [Related]
5. Factor VII for excessive bleeding following congenital heart disease surgery.
Changlani DK; Devendaran V; Murmu UC; Ganesan S; Varghese R; Kumar RS
Asian Cardiovasc Thorac Ann; 2012 Apr; 20(2):120-5. PubMed ID: 22499956
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery.
Agarwal HS; Bennett JE; Churchwell KB; Christian KG; Drinkwater DC; He Y; Taylor MB
Ann Thorac Surg; 2007 Jul; 84(1):161-8. PubMed ID: 17588404
[TBL] [Abstract][Full Text] [Related]
7. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Moll JJ; Krajewski W; Jarosik P
Pediatr Crit Care Med; 2004 May; 5(3):246-50. PubMed ID: 15115562
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.
Karsies TJ; Nicol KK; Galantowicz ME; Stephens JA; Kerlin BA
Ann Thorac Surg; 2010 Feb; 89(2):570-6. PubMed ID: 20103344
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery.
Wittenstein B; Ng C; Ravn H; Goldman A
Pediatr Crit Care Med; 2005 Jul; 6(4):473-6. PubMed ID: 15982438
[TBL] [Abstract][Full Text] [Related]
10. Recombinant activated factor VII in cardiac surgery: single-center experience.
Singh SP; Chauhan S; Choudhury M; Malik V; Choudhary SK
Asian Cardiovasc Thorac Ann; 2014 Feb; 22(2):148-54. PubMed ID: 24585784
[TBL] [Abstract][Full Text] [Related]
11. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Tomita E; Takase H; Tajima K; Suematsu Y
Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
13. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
14. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
Guzzetta NA; Russell IA; Williams GD
Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
[TBL] [Abstract][Full Text] [Related]
15. [New possibilities in the postoperative measures to prevent bleeding in cardiac surgery. Will the recombinant activated factor VII improve surgical results?].
Skalski JH; Czapla J; Nadziakiewicz P; Kaczmarski J; Zembala M
Przegl Lek; 2002; 59(11):941-5. PubMed ID: 12715727
[TBL] [Abstract][Full Text] [Related]
16. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
17. Coagulation considerations for infants and children undergoing cardiopulmonary bypass.
Eaton MP; Iannoli EM
Paediatr Anaesth; 2011 Jan; 21(1):31-42. PubMed ID: 21155925
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
19. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
20. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation.
Niebler RA; Punzalan RC; Marchan M; Lankiewicz MW
Pediatr Crit Care Med; 2010 Jan; 11(1):98-102. PubMed ID: 19561557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
